KMI
73
4
GM
61
4
FE
37
3
ALLE
25
4
JPM
62
3
AMG
52
3
DOW
47
3
MMC
50
4
AIG
38
2
RHI
50
2
MCK
59
3
PPG
60
3
GS
58
5
WMB
62
2
TRIP
66
2
FTI
63
2
GIS
37
2
SRE
47
7
ROK
48
2
FLR
52
2
KMI
73
4
GM
61
4
FE
37
3
ALLE
25
4
JPM
62
3
AMG
52
3
DOW
47
3
MMC
50
4
AIG
38
2
RHI
50
2
MCK
59
3
PPG
60
3
GS
58
5
WMB
62
2
TRIP
66
2
FTI
63
2
GIS
37
2
SRE
47
7
ROK
48
2
FLR
52
2
Financhill
Back

Keros Therapeutics 10K Form

Sell
10

KROS
Keros Therapeutics

Last Price:
$16.76
Seasonality Move:
16.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $151K
Cash Flow: $-30.9M
Price / Cash Flow: 0
Annual Sales: $13.57
Price / Book: 1.27

Profitability

EPS (TTM): -5.21000
Net Income (TTM): $-181.6M
Gross Margin: --
Return on Equity: -44.6%
Return on Assets: -40.96%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Research & Development expenses have been 89,574.83% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KROS is -101,319.21% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 19.03
Quick Ratio: 18.36

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Sell
10
Keros Therapeutics (KROS) is a Sell

Is Keros Therapeutics a Buy or a Sell?